Reliability testing of the Six Area, Six Sign Atopic Dermatitis severity score

被引:42
作者
Charman, CR [1 ]
Venn, AJ
Williams, HC
机构
[1] Queens Med Ctr, Dept Dermatol, Nottingham NG7 2UH, England
[2] Univ Nottingham, Nottingham NG7 2RD, England
关键词
atopic eczema; reliability; SASSAD; severity score;
D O I
10.1046/j.1365-2133.2002.04644.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
Background The Six Area, Six Sign Atopic Dermatitis (SASSAD) severity score is an objective atopic eczema severity index designed principally to assess response to treatment in therapeutic trials. Validity has been demonstrated in single and multicentre clinical trials, although data on the reliability of the index have not previously been published. Objectives To assess inter- and intraobserver variability of the SASSAD index. Methods Six observers with experience in the assessment of atopic eczema were each asked to score disease severity in six patients with moderate to severe atopic eczema using the SASSAD index. Repeat observations were carried out on randomly selected patients by each observer to estimate intraobserver variation. Results The interobserver variation in total SASSAD scores for each patient ranged from 7 to 30 (median 15.5) out of a maximum possible score of 108. The intraclass correlation coefficient r (i) for the total scores among all six observers was quite high at 0.70, although interobserver agreement for individual components of the index was poor to moderate. The maximum recorded intraobserver variation in total SASSAD score in any of the examined patients was 8 units. Conclusions As with many other tested atopic eczema scoring indices, the SASSAD index is subject to significant interobserver variation, reflecting the difficulties in reliably assessing eczema severity objectively.
引用
收藏
页码:1057 / 1060
页数:4
相关论文
共 16 条
[1]
Cyclosporine in severe childhood atopic dermatitis: A multicenter study [J].
BerthJones, J ;
Finlay, AY ;
Zaki, I ;
Tan, B ;
Goodyear, H ;
LewisJones, S ;
Cork, MJ ;
Bleehen, SS ;
Salek, MS ;
Allen, BR ;
Friedmann, P ;
Harper, J ;
Camp, RDR ;
Smith, S ;
GrahamBrown, RAC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (06) :1016-1021
[2]
FAILURE OF TERFENADINE IN RELIEVING THE PRURITUS OF ATOPIC-DERMATITIS [J].
BERTHJONES, J ;
GRAHAMBROWN, RAC .
BRITISH JOURNAL OF DERMATOLOGY, 1989, 121 (05) :635-637
[4]
Outcome measures of disease severity in atopic eczema [J].
Charman, C ;
Williams, H .
ARCHIVES OF DERMATOLOGY, 2000, 136 (06) :763-769
[5]
[6]
FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619
[7]
CYCLOSPORINE IN ATOPIC-DERMATITIS - TIME TO RELAPSE AND EFFECT OF INTERMITTENT THERAPY [J].
GRANLUND, H ;
ERKKO, P ;
SINISALO, M ;
REITAMO, S .
BRITISH JOURNAL OF DERMATOLOGY, 1995, 132 (01) :106-112
[8]
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis [J].
Hanifin, JM ;
Thurston, M ;
Omoto, M ;
Cherill, R ;
Tofte, SJ ;
Graeber, M .
EXPERIMENTAL DERMATOLOGY, 2001, 10 (01) :11-18
[9]
Cyclosporin for severe childhood atopic dermatitis:: short course versus continuous therapy [J].
Harper, JI ;
Ahmed, I ;
Barclay, G ;
Lacour, M ;
Hoeger, P ;
Cork, MJ ;
Finlay, AY ;
Wilson, NJE ;
Graham-Brown, RAC ;
Sowden, JM ;
Beard, AL ;
Sumner, MJ ;
Berth-Jones, J .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 142 (01) :52-58
[10]
Clinical validation and guidelines for the SCORAD index: Consensus report of the European task force on atopic dermatitis [J].
Kunz, B ;
Oranje, AP ;
Labreze, L ;
Stalder, JF ;
Ring, J ;
Taieb, A .
DERMATOLOGY, 1997, 195 (01) :10-19